CN112424186A - 基质金属蛋白酶(mmp)抑制剂及其使用方法 - Google Patents

基质金属蛋白酶(mmp)抑制剂及其使用方法 Download PDF

Info

Publication number
CN112424186A
CN112424186A CN201980047333.0A CN201980047333A CN112424186A CN 112424186 A CN112424186 A CN 112424186A CN 201980047333 A CN201980047333 A CN 201980047333A CN 112424186 A CN112424186 A CN 112424186A
Authority
CN
China
Prior art keywords
compound
mixture
hydrogen
ring
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980047333.0A
Other languages
English (en)
Chinese (zh)
Inventor
杨文津
张凯为
刘素莹
蔡政翰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yida Biotechnology Usa Inc
Original Assignee
Yida Biotechnology Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yida Biotechnology Usa Inc filed Critical Yida Biotechnology Usa Inc
Publication of CN112424186A publication Critical patent/CN112424186A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980047333.0A 2018-05-15 2019-05-14 基质金属蛋白酶(mmp)抑制剂及其使用方法 Pending CN112424186A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671753P 2018-05-15 2018-05-15
US62/671,753 2018-05-15
PCT/US2019/032127 WO2019222154A1 (en) 2018-05-15 2019-05-14 Matrix metalloproteinase (mmp) inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CN112424186A true CN112424186A (zh) 2021-02-26

Family

ID=66690981

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201980047333.0A Pending CN112424186A (zh) 2018-05-15 2019-05-14 基质金属蛋白酶(mmp)抑制剂及其使用方法
CN201980047375.4A Active CN112424192B (zh) 2018-05-15 2019-05-14 基质金属蛋白酶(mmp)抑制剂及其应用方法
CN202411619226.XA Pending CN119462623A (zh) 2018-05-15 2019-05-14 基质金属蛋白酶（mmp）抑制剂及其应用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201980047375.4A Active CN112424192B (zh) 2018-05-15 2019-05-14 基质金属蛋白酶(mmp)抑制剂及其应用方法
CN202411619226.XA Pending CN119462623A (zh) 2018-05-15 2019-05-14 基质金属蛋白酶（mmp）抑制剂及其应用方法

Country Status (20)

Country Link
US (6) US20190352288A1 (https=)
EP (4) EP4335499A3 (https=)
JP (4) JP7343571B2 (https=)
KR (3) KR102861502B1 (https=)
CN (3) CN112424186A (https=)
AU (3) AU2019269409B2 (https=)
BR (1) BR112020023269A2 (https=)
CA (2) CA3100320A1 (https=)
DK (2) DK3793995T3 (https=)
ES (2) ES2978192T3 (https=)
FI (2) FI3793992T3 (https=)
HU (2) HUE066619T2 (https=)
LT (1) LT3793995T (https=)
MY (1) MY199200A (https=)
PL (1) PL3793995T3 (https=)
PT (2) PT3793992T (https=)
SG (2) SG11202011316RA (https=)
SI (1) SI3793995T1 (https=)
TW (3) TWI827601B (https=)
WO (2) WO2019222157A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532102B2 (en) * 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
SI3793995T1 (sl) 2018-05-15 2024-05-31 Foresee Pharmaceuticals Usa, Inc. Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe
CA3158234A1 (en) * 2019-11-14 2021-05-20 Foresee Pharmaceuticals Co., Ltd. Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
EP4351566A4 (en) * 2021-06-08 2025-04-23 Foresee Pharmaceuticals USA, Inc. SAFE ADMINISTRATION OF MMP-12 INHIBITOR
TW202313011A (zh) * 2021-06-08 2023-04-01 逸達生物科技股份有限公司 Mmp抑制劑於治療急性呼吸窘迫綜合症之用途
EP4198033A1 (en) 2021-12-14 2023-06-21 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2023110473A1 (en) 2021-12-14 2023-06-22 Basf Se Heterocyclic compounds for the control of invertebrate pests

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067996A1 (en) * 2002-10-04 2004-04-08 James Sheppeck Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
WO2004108086A2 (en) * 2003-06-05 2004-12-16 Bristol-Myers Squibb Company HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE)
CN101014338A (zh) * 2004-08-19 2007-08-08 奎斯特药物服务 作为巨噬细胞弹性蛋白酶抑制剂的5－[3－(4－苄氧基苯基硫代)－呋喃－2－基]－咪唑烷－2,4－二酮和类似物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2482618A1 (fr) 1980-05-16 1981-11-20 Inst Corps Gras Iterg Procede de conjugaison catalytique de corps gras polyinsatures, produits obtenus et application
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
EP1150975A1 (en) 1998-12-31 2001-11-07 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
EP1288199A4 (en) 2000-04-28 2005-10-12 Shionogi & Co INHIBITORS OF MMP-12
JP2004527511A (ja) 2001-03-15 2004-09-09 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼ阻害剤
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US6890915B2 (en) 2001-05-25 2005-05-10 Bristol-Myers Squibb Pharma Company Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
EP1394159A1 (fr) 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
EP2797002A4 (en) 2011-12-21 2015-05-20 Panasonic Corp DATA PROCESSING DEVICE, DATA TRANSMISSION DEVICE, DATA PROCESSING SYSTEM, DATA PROCESSING METHOD AND DATA TRANSMISSION METHOD
SI3793995T1 (sl) * 2018-05-15 2024-05-31 Foresee Pharmaceuticals Usa, Inc. Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067996A1 (en) * 2002-10-04 2004-04-08 James Sheppeck Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
WO2004108086A2 (en) * 2003-06-05 2004-12-16 Bristol-Myers Squibb Company HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE)
CN101014338A (zh) * 2004-08-19 2007-08-08 奎斯特药物服务 作为巨噬细胞弹性蛋白酶抑制剂的5－[3－(4－苄氧基苯基硫代)－呋喃－2－基]－咪唑烷－2,4－二酮和类似物

Also Published As

Publication number Publication date
CN112424192A (zh) 2021-02-26
AU2019269409B2 (en) 2023-11-23
EP3793995A1 (en) 2021-03-24
FI3793992T3 (fi) 2024-04-17
TW202003493A (zh) 2020-01-16
EP3793992A1 (en) 2021-03-24
EP4335499A3 (en) 2024-05-15
KR20210020011A (ko) 2021-02-23
TW202002975A (zh) 2020-01-16
HUE066619T2 (hu) 2024-08-28
AU2019269409A1 (en) 2021-01-07
SG11202011318QA (en) 2020-12-30
EP4335499A2 (en) 2024-03-13
PT3793992T (pt) 2024-05-13
TW202400584A (zh) 2024-01-01
CA3100320A1 (en) 2019-11-21
US20240018131A1 (en) 2024-01-18
KR20250021604A (ko) 2025-02-13
BR112020023269A2 (pt) 2021-02-23
JP2023164905A (ja) 2023-11-14
KR20210020897A (ko) 2021-02-24
SI3793995T1 (sl) 2024-05-31
ES2984594T3 (es) 2024-10-30
WO2019222154A1 (en) 2019-11-21
TWI895726B (zh) 2025-09-01
JP7344959B2 (ja) 2023-09-14
US12258335B1 (en) 2025-03-25
HUE066627T2 (hu) 2024-08-28
PT3793995T (pt) 2024-05-02
PL3793995T3 (pl) 2024-05-06
AU2019270975B2 (en) 2023-12-14
AU2024200323B2 (en) 2025-06-05
EP4349332A2 (en) 2024-04-10
US20210214340A1 (en) 2021-07-15
US20190352288A1 (en) 2019-11-21
US11739080B2 (en) 2023-08-29
AU2019270975A1 (en) 2021-01-07
MY199200A (en) 2023-10-19
DK3793995T3 (da) 2024-04-08
US12215096B2 (en) 2025-02-04
JP7656669B2 (ja) 2025-04-03
EP4349332A3 (en) 2024-05-15
AU2024200323A1 (en) 2024-02-01
SG11202011316RA (en) 2020-12-30
CN119462623A (zh) 2025-02-18
JP2021523241A (ja) 2021-09-02
TWI798435B (zh) 2023-04-11
US10851089B2 (en) 2020-12-01
US20250115590A1 (en) 2025-04-10
JP7343571B2 (ja) 2023-09-12
TWI827601B (zh) 2024-01-01
ES2978192T3 (es) 2024-09-06
JP2023164924A (ja) 2023-11-14
CN112424192B (zh) 2024-11-26
CA3100319A1 (en) 2019-11-21
US20190352287A1 (en) 2019-11-21
LT3793995T (lt) 2024-04-25
KR102761591B1 (ko) 2025-01-31
EP3793995B1 (en) 2024-01-10
WO2019222157A1 (en) 2019-11-21
KR102861502B1 (ko) 2025-09-18
EP3793992B1 (en) 2024-01-10
JP2021523240A (ja) 2021-09-02
DK3793992T3 (da) 2024-04-08
FI3793995T3 (fi) 2024-04-17

Similar Documents

Publication Publication Date Title
JP7656669B2 (ja) マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
JP5898230B2 (ja) Ｓ−ニトロソグルタチオンレダクターゼ阻害薬としての新規な置換二環芳香族化合物
WO2019231290A1 (ko) 신규한 화합물 및 이를 포함하는 약학적 조성물
CN115667227B (zh) 基质金属蛋白酶(mmp)抑制剂及其使用方法
RU2797558C2 (ru) Ингибиторы матриксной металлопротеиназы (mmp) и способы их применения
RU2840074C1 (ru) Ингибиторы матриксной металлопротеиназы (ммр) и способы их применения
HK40107395A (en) Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
HK40050775B (en) Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
HK40050775A (en) Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
HK40050772A (en) Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
HK40050772B (en) Matrix metalloproteinase (mmp) inhibitors and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination